Project Grant K99AI191990
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,400 in funding to Brigham & Women's Hospital Inc. to conduct research on the role of antibody-dependent innate effector function in tuberculosis (TB) disease progression among individuals co-infected with HIV. The 5-year research program aims to comprehensively investigate how perturbations to...
- This federal Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $170,411 in funding from August 8, 2025 to July 31, 2030 to support mentorship and training of early career investigators in translational virological research focused on HIV persistence, therapeutic interventions, and drug resistance. The grant recipient, Brigham & Women's Hospital Inc., will leverage...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $884,453 Project Grant to Brigham & Women's Hospital Inc. to develop a rapid, cost-effective point-of-care (POC) diagnostic test for Hepatitis C Virus (HCV) detection. The 5-year project, which commenced on November 22, 2024, aims to create a highly sensitive and specific HCV antigen (Ag) testing solution that can streamline...
- This federal Project Grant award of $1,210,300 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of novel polyvalent HIV vaccines to protect people who inject drugs (PWID) against intravenous HIV transmission. The project aims to create a vaccine that can elicit high levels of immune responses to rapidly clear multiple HIV strains that may be transmitted through needle use. The grant was awarded to Beth...
- This federal Project Grant award for $711,993.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to examine the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis in people living with HIV (PWH). The research aims to assess how MTB disease influences the development of broadly neutralizing HIV-1 antibodies, the emergence of NAb-resistant viral...
- The federal Cooperative Agreement award of $443,527 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), is to support research at Brigham & Women's Hospital Inc. to advance the understanding and clinical care of antibiotic-induced delayed-type drug hypersensitivity reactions (DTDHR). The award will fund a prospective longitudinal translational study of DTDHR patients and matched controls,...
- The Defense Health Agency awarded a $1,789,999 Project Grant to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, under the Military Medical Research and Development program (CFDA 12.420). The grant aims to develop a novel approach to increase fetal and embryonic hemoglobins for the treatment of sickle cell anemia. The project will be conducted over a 3-year period from March 1, 2025, to February 29, 2028. As a prominent academic medical center and...
- The Brigham & Women's Hospital Inc. was awarded a $586,619 Cooperative Agreement from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to develop CPG-DNA, a radiation medical countermeasure that can restore anti-microbial immune function and reduce delayed effects of acute radiation exposure in mice. The project aims to leverage systems biology research methods to explore detailed changes in the hematopoietic and immune systems, with a...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $824,331 Project Grant to Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The research aims to improve understanding of the establishment and persistence of latent viral reservoirs in HIV-infected individuals, particularly the role of naive CD4+ T cells, in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
The Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, was awarded a $135,540 federal Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research focused on the development of long-acting injectable delivery systems for antiretroviral therapy to prevent and treat HIV/AIDS. The grant, awarded on September 3, 2025, will support the recipient's efforts to identify biodegradable long-acting injectables that can provide sustained delivery of a broad spectrum of antiretroviral drugs for at least 6 months, with the goal of improving accessibility and effectiveness of HIV prevention and treatment globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $135.5k | 9/3/25 |